MOTS-C
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Mitochondrial-derived peptide; AMPK activator and exercise mimetic promoting metabolic homeostasis, insulin sensitivity, and age-dependent physical performance
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Mitochondrial Open Reading Frame of the 12S rRNA Type-c, "Exercise in a Pill" |
| Category | Metabolic / Anti-Aging / Mitochondrial |
| Sequence | MRWQEMGYIFYPRKLR (16 amino acids) |
| Molecular Weight | 2174.62 Da |
| Molecular Formula | C₁₀₁H₁₅₂N₂₈O₂₂S₂ |
| PubChem CID | 146675088 |
| Administration | SubQ |
| Typical Dose Range | 5–10 mg SubQ 3x/week; or 10 mg once weekly (pulse) |
| Half-Life | Not well characterized; short plasma half-life |
| Storage | Lyophilized: -20°C, 12–24 months; Reconstituted: 2–8°C, use within 2–7 days (unstable in solution; do NOT shake) |
| FDA Status | Research-only; not FDA-approved. CB4211 (MOTS-c analog) entered Phase 1 clinical trial |
| WADA Status | Prohibited under S0 (Non-Approved Substances) |
Mechanism of Action
MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene, discovered by Changhan Lee in 2015. Its primary mechanism is activation of AMPK (the cell's master metabolic switch) via an indirect route: MOTS-c inhibits the folate cycle, causing accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which directly activates AMPK. This triggers glucose uptake (GLUT4 translocation), fatty acid oxidation, and suppression of anabolic pathways — parallel to Metformin but through a different molecular trigger (PMID-25738459).
A paradigm-shifting 2018 discovery showed that MOTS-c undergoes AMPK-dependent nuclear translocation under metabolic stress. In the nucleus, MOTS-c interacts with ARE (Antioxidant Response Element) and ETS transcription factor motifs, directly regulating adaptive nuclear gene expression. This established a novel mitochondria-to-nucleus retrograde signaling pathway — the first demonstration that a mitochondrial-encoded peptide can directly modulate the nuclear genome (PMID-29983246).
As an exercise mimetic, MOTS-c replicates exercise-induced metabolic hallmarks in preclinical models: enhanced endurance, thermogenesis (WAT browning), and insulin sensitivity. A landmark 2021 study demonstrated that exercise induces endogenous MOTS-c expression in skeletal muscle and circulation in both mice and humans, and that late-life MOTS-c treatment (initiated at 23.5 months in mice) reversed age-dependent physical decline (PMID-33473109).
MOTS-c also inhibits myostatin expression through the CK2-PTEN-mTORC2-AKT-FOXO1 pathway, reducing muscle atrophy in high-fat-diet models while simultaneously promoting fat oxidation — enabling simultaneous muscle preservation and fat reduction (PMID-33554779).
Key Research Areas
-
Exercise Mimesis and Aging — Late-life MOTS-c treatment reversed age-dependent physical decline in mice; exercise upregulates MOTS-c in human skeletal muscle (Nature Communications, Lee lab) (PMID-33473109).
-
Metabolic Homeostasis — The foundational Lee et al. (2015) study showed MOTS-c prevents obesity, insulin resistance, and metabolic dysfunction in HFD mice via AMPK activation (PMID-25738459).
-
Nuclear Retrograde Signaling — MOTS-c translocates to the nucleus via AMPK to regulate stress-responsive gene expression (Cell Metabolism, Lee lab) (PMID-29983246).
-
Myostatin Inhibition and Sarcopenia — MOTS-c reduces muscle atrophy signaling via CK2-PTEN-mTORC2 pathway, preserving muscle mass under metabolic stress (PMID-33554779).
-
Insulin Resistance and Diabetes — MOTS-c relieves hyperglycemia and improves insulin sensitivity in gestational diabetes models (PMID-34798268).
-
Anti-Cancer — MOTS-c suppresses ovarian cancer progression via LARS1 degradation and mTORC1 inhibition (PMID-39321430).
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human observational | 1 | Exercise-induced MOTS-c in human muscle (component of PMID-33473109) |
| Animal in vivo | 4 | Metabolic, aging, myostatin, GDM models |
| In vitro / mechanistic | 1 | Nuclear translocation (Cell Metabolism) |
| Narrative reviews | 4 | Metabolic disorders, therapeutic applications, diabetes/aging |
| Total vault studies | 10 |
The evidence base for MOTS-c is strong preclinically with emerging human data. Two publications in Cell Metabolism and Nature Communications (Lee lab) provide high-impact foundational evidence. Human data is limited to observational exercise biomarker measurements — no human intervention trials of MOTS-c itself have been published (CB4211, a MOTS-c analog, entered Phase 1). Key strength: Evidence comes from multiple independent labs, not single-group dependent. Key limitation: All therapeutic data is from mouse models.
Clinical Applications
- Fat Loss — AMPK-mediated fatty acid oxidation and WAT browning
- Weight Management — Simultaneous fat reduction and muscle preservation
- Type 2 Diabetes — Insulin sensitization via GLUT4 translocation
- Metabolic Syndrome — Broad metabolic reprogramming
- Sarcopenia — Myostatin inhibition and muscle homeostasis
- Anti-Aging — Reversal of age-dependent physical decline
Protocols Using This Peptide
- Metabolic Reset Protocol — Core exercise mimetic peptide
- Weight Loss Protocol — AMPK activation for metabolic support
- Anti-Aging Daily Protocol — Mitochondrial support and longevity
Ageless Peps Products
- AP-MOTSC-10 — MOTS-C 10mg Vial, $47 retail
Dosing Reference
Research Dosing Ranges
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ | 5–10 mg | 3x/week | 4 weeks on / 4 weeks off | Practitioner guides; extrapolated from mouse data |
| SubQ | 10 mg | 1x/week (pulse) | Ongoing | Practitioner consensus |
| SubQ | 25 mg daily (CB4211 analog) | Daily | 4 weeks | CB4211 Phase 1 trial |
Cycling
Standard: 4 weeks on, 4 weeks off. Pulse dosing (10 mg once weekly) is an alternative for sustained metabolic support with lower total dose. No cycling protocol in peer-reviewed literature; guidance from practitioner consensus.
Contraindications & Safety
- Contraindications: Active malignancy — context-dependent (MOTS-c shows anti-tumor effects in ovarian cancer but theoretical pro-metabolic risk in other cancers). Use clinical judgment.
- Common side effects: Injection site reactions, flu-like symptoms (transient, resolves within first week)
- Drug interactions: Theoretical additive hypoglycemia with insulin, sulfonylureas, or metformin. Caution with AMPK-activating drugs (additive effect).
- Pregnancy/nursing: Not recommended; no safety data. Note: GDM study showed benefit in mouse model but no human pregnancy data.
- Special populations: Reconstituted MOTS-c is unstable — use within 2-7 days. Do NOT shake; gentle swirling preserves alpha-helical structure.
Safety profile based entirely on preclinical data. No completed human safety trials for MOTS-c peptide. CB4211 (analog) Phase 1 data not yet published.
Cancer Considerations
CAUTION — AMPK dual role in cancer. MOTS-C suppresses ovarian cancer progression via LARS1 degradation and mTORC1 inhibition (PMID-39321430). However, AMPK activation has a DUAL ROLE in breast cancer specifically: anti-tumor effects (mTOR inhibition, aromatase suppression) coexist with pro-tumor effects (breast cancer stem cell promotion via TWIST/NANOG/SOX2). Do NOT extrapolate ovarian cancer benefit to breast cancer. Use only with oncologist approval in patients with active malignancy. The cancer effect is likely tumor-type and stage-dependent.
Synergistic Combinations
- Epitalon + Thymosin Alpha-1 + MOTS-C — Longevity stack: telomere + immune + mitochondrial support
- GHK-Cu + MOTS-C — Anti-aging: gene modulation + metabolic optimization
- Tirzepatide + MOTS-C — Synergistic weight loss: incretin + AMPK pathways (theoretical)
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| PMID-25738459 | MOTS-c promotes metabolic homeostasis (Lee foundational) | 2015 | Animal in vivo |
| PMID-29983246 | MOTS-c nuclear translocation (Cell Metabolism) | 2018 | In vitro |
| PMID-31378979 | MOTS-c: Mitochondrial-Encoded Regulator of the Nucleus | 2019 | Narrative Review |
| PMID-33473109 | MOTS-c: exercise-induced regulator of physical decline | 2021 | Animal + Human obs. |
| PMID-33554779 | MOTS-c reduces myostatin and muscle atrophy | 2021 | Animal in vivo |
| PMID-34798268 | MOTS-c relieves hyperglycemia in GDM | 2022 | Animal in vivo |
| PMID-36677050 | MOTS-c Functionally Prevents Metabolic Disorders | 2023 | Narrative Review |
| PMID-36761202 | MOTS-c: promising for therapeutic exploitation | 2023 | Narrative Review |
| PMID-36824008 | MOTS-c, Diabetes, and Aging-Related Diseases | 2023 | Narrative Review |
| PMID-39321430 | MOTS-c Suppresses Ovarian Cancer | 2024 | Animal in vivo |
Related
#peptide #metabolic #anti-aging #mitochondrial #subq